H. Abken

U. Schlötzer-Schrehardt, M. Paulsson, A. Niehoff, 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Cyclooxygenases Inhibitors Efficiently Induce Cardiomyogenesis in Human Pluripotent Stem Cells

J. Hescheler, H. Abken, A. Sachinidis, 2020, Cells.

Antigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T Cells

H. Abken, A. Hombach, M. Chmielewski, 2013, Front. Immunol..

The beating heart of melanomas: a minor subset of cancer cells sustains tumor growth

H. Abken, P. Schmidt, 2011, Oncotarget.

Combining cytokine-induced killer cells with vaccination in cancer immunotherapy: more than one plus one?

I. Schmidt-Wolf, H. Abken, S. Thanendrarajan, 2011, Leukemia research.

Mitochondrial DNA mutations induce mitochondrial biogenesis and increase the tumorigenic potential of Hodgkin and Reed-Sternberg cells.

Robert W. Taylor, J. Elson, R. Wiesner, 2020, Carcinogenesis.

Short DNA sequences from the cytoplasm of mouse tumor cells induce immortalization of human lymphocytes in vitro.

K. Willecke, H. Abken, C. Bützler, 1993, Proceedings of the National Academy of Sciences of the United States of America.

CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe.

H. Abken, R. Debets, D. Gilham, 2012, Trends in molecular medicine.

Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T‐cells

E. Rieber, S. Güneş, A. Temme, 2007, The Prostate.

Immortalization of human lymphocytes by fusion with cytoplasts of transformed mouse L cells

K. Willecke, H. Abken, H. Jungfer, 1986, The Journal of cell biology.

Expression of TRX1 optimizes the antitumor functions of human CAR T cells and confers resistance to a pro-oxidative tumor microenvironment

B. Niesler, Y. Samstag, H. Abken, 2022, Frontiers in Immunology.

Fatal Hodgkin and non-Hodgkin lymphoma associated with persistent Epstein-Barr virus in four brothers.

K. Donhuijsen, G. Bornkamm, H. Abken, 1988, Annals of internal medicine.

CAR T cell therapy becomes CHIC: “cytokine help intensified CAR” T cells

H. Abken, Simone Thomas, 2023, Frontiers in Immunology.

Generation of an NFκB-Driven Alpharetroviral “All-in-One” Vector Construct as a Potent Tool for CAR NK Cell Therapy

A. Schambach, I. Sandalcioglu, Johann Meyer, 2021, Frontiers in Immunology.

Gene Transfer into T Cells

H. Abken, D. Gilham, 2014 .

The proteasome inhibitor bortezomib sensitizes melanoma cells toward adoptive CTL attack.

O. Coutelle, H. Abken, M. Krönke, 2010, Cancer research.

A novel type of unstable homogeneously staining region with a head-to-tail arrangement: spontaneous decay and reintegration of DNA elements into a plethora of new chromosomal sites.

J. Wienberg, U. Weidle, F. Grummt, 1995, Cytogenetics and cell genetics.

SMAC mimetic potentiates tumor susceptibility towards natural killer cell-mediated killing

H. Abken, M. Krönke, H. Kashkar, 2013 .

Redirected T cells that target pancreatic adenocarcinoma antigens eliminate tumors and metastases in mice.

P. Altevogt, Z. Eshhar, H. Abken, 2012, Gastroenterology.

Antibody-IL2 fusion proteins for tumor targeting.

H. Abken, A. Hombach, 2012, Methods in molecular biology.

A procedure to standardize CAT reporter gene assay

Hinrich Abken, Barbara Reifenrath, H. Abken, 1992, Nucleic Acids Res..

Chimeric anti-TAG72 receptors with immunoglobulin constant Fc domains and gamma or zeta signalling chains.

V. Diehl, H. Abken, C. Pohl, 1998, International journal of molecular medicine.

A novel strategy in the elimination of disseminated melanoma cells: chimeric receptors endow T cells with tumor specificity.

U. Reinhold, H. Abken, A. Hombach, 2001, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Non-canonical effector functions of the T-memory-like T-PLL cell are shaped by cooperative TCL1A and TCR signaling.

T. Aittokallio, D. Mougiakakos, M. Hallek, 2020, Blood.

Antigen‐presenting human B cells are expanded in inflammatory conditions

M. Hallek, M. Herling, S. Theurich, 2017, Journal of leukocyte biology.

T-Bodies: Antibody-Based Engineered T-Cell Receptors

Z. Eshhar, H. Abken, D. Gilham, 2014 .

Can combined T-cell- and antibody-based immunotherapy outsmart tumor cells?

U. Reinhold, S. Ferrone, H. Abken, 1998, Immunology today.

Chimeric T-cell receptors: highly specific tools to target cytotoxic T-lymphocytes to tumour cells.

U. Reinhold, H. Abken, C. Pohl, 1997, Cancer treatment reviews.

Blocking CD30 on T Cells by a Dual Specific CAR for CD30 and Colon Cancer Antigens Improves the CAR T Cell Response against CD30- Tumors.

H. Abken, A. Hombach, G. Rappl, 2019, Molecular therapy : the journal of the American Society of Gene Therapy.

Superior Therapeutic Index in Lymphoma Therapy: CD30(+) CD34(+) Hematopoietic Stem Cells Resist a Chimeric Antigen Receptor T-cell Attack.

H. Abken, B. Giebel, A. Görgens, 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

IL-2 "Backpacking" Invigorates Treg Cells to Prevent Allograft Rejection.

H. Abken, 2021, Transplantation.

Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease.

H. Heslop, C. Rooney, H. Abken, 2007, Blood.

Can Redirected T Cells Outsmart Aggressive Melanoma? The Promise and Challenge of Adoptive Cell Therapy

H. Abken, J. Makalowski, 2015 .

Adoptive Cell Therapy of Melanoma: The Challenges of Targeting the Beating Heart

H. Abken, J. Makalowski, 2013 .

T-cell activation by recombinant immunoreceptors: Impact of the intracellular signalling domain on the stability of receptor expression and antigen-specific activation of grafted T cells

H. Abken, A. Hombach, C. Heuser, 2003, Gene Therapy.

Specific lysis of melanoma cells by receptor grafted T cells is enhanced by anti-idiotypic monoclonal antibodies directed to the scFv domain of the receptor.

U. Reinhold, S. Ferrone, X. Wang, 1999, The Journal of investigative dermatology.

CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma.

U. Höpken, W. Uckert, A. Rehm, 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

Adoptive immunotherapy with redirected T cells produces CCR7- cells that are trapped in the periphery and benefit from combined CD28-OX40 costimulation.

H. Abken, A. Hombach, M. Chmielewski, 2013, Human gene therapy.

Intra-tumoral production of IL18, but not IL12, by TCR-engineered T cells is non-toxic and counteracts immune evasion of solid tumors

H. Abken, R. Debets, C. Berrevoets, 2017, Oncoimmunology.

B7‐1 and B7‐2 act differentially in the induction of a T cell response: Their impact for a HLA‐matched and HLA‐mismatched anti‐tumor immunotherapy

B. Seliger, H. Abken, K. Kronfeld, 2005, International Journal of Cancer.

B7/CD28 Costimulation of T Cells Induces a Distinct Proteome Pattern*

B. Seliger, E. Hochleitner, F. Lottspeich, 2005, Molecular & Cellular Proteomics.

Stability and activity of MCSP-specific chimeric antigen receptors (CARs) depend on the scFv antigen-binding domain and the protein backbone

G. Schuler, G. Fey, H. Abken, 2015, Cancer Immunology, Immunotherapy.

T cell targeting of TAG72+ tumor cells by a chimeric receptor with antibody-like specificity for a carbohydrate epitope.

V. Diehl, H. Abken, C. Pohl, 1997, Gastroenterology.

Difficulties in Targeting the Beating Heart

H. Abken, J. Makalowski, 2014 .

IL7-IL12 Engineered Mesenchymal Stem Cells (MSCs) Improve A CAR T Cell Attack Against Colorectal Cancer Cells

H. Abken, Ulf Geumann, A. Hombach, 2020, Cells.

Extensive amplification of human regulatory T cells alters their functional capacities and targets them to the periphery.

A. Schmidt, H. Abken, C. Mauch, 2008, Rejuvenation research.

CAR Triggered Release of Type-1 Interferon Limits CAR T-Cell Activities by an Artificial Negative Autocrine Loop

H. Abken, Hong Pan, J. Hartley, 2022, Cells.

T Cells Engineered with a Cytomegalovirus-Specific Chimeric Immunoreceptor

K. Kaufmann, A. Ensser, M. Lehner, 2010, Journal of Virology.

Generation, expression, and monitoring of recombinant immune receptors for use in cellular immunotherapy.

H. Abken, A. Hombach, C. Heuser, 2003, Methods in molecular biology.

Genetic Engineering of Autologous or Allogeneic Immune Effector Cells

H. Abken, K. Benabdellah, Simone Thomas, 2022, The EBMT/EHA CAR-T Cell Handbook.

Grafting T cells with tumor specificity: the chimeric receptor strategy for use in immunotherapy of malignant diseases.

U. Reinhold, H. Abken, C. Pohl, 1999, Hybridoma.

The Express Drivers: Chimeric Antigen Receptor-Redirected T Cells Make It to the Clinic

W. Wels, H. Abken, K. Kühlcke, 2014 .

The weal and woe of costimulation in the adoptive therapy of cancer with chimeric antigen receptor (CAR)-redirected T cells.

H. Abken, A. Holzinger, A. Hombach, 2013, Current molecular medicine.

Rational development of high-affinity T-cell receptor-like antibodies

V. Cerundolo, E. Jones, A. McMichael, 2009, Proceedings of the National Academy of Sciences.

Cancer gene therapy with T cell receptors and chimeric antigen receptors.

H. Abken, E. Morris, H. Stauss, 2015, Current opinion in pharmacology.

Receptor-targeted lentiviral vectors are exceptionally sensitive toward the biophysical properties of the displayed single-chain Fv.

A. Plückthun, A. Honegger, H. Abken, 2015, Protein engineering, design & selection : PEDS.

CXCR5 CAR-T cells simultaneously target B cell non-Hodgkin’s lymphoma and tumor-supportive follicular T helper cells

U. Höpken, W. Uckert, A. Rehm, 2021, Nature communications.

T cells redirected by a CD3ζ chimeric antigen receptor can establish self-antigen-specific tumour protection in the long term

H. Abken, A. Hombach, M. Chmielewski, 2012, Gene Therapy.

Antigen receptor-redirected T cells derived from hematopoietic precursor cells lack expression of the endogenous TCR/CD3 receptor and exhibit specific antitumor capacities

H. Abken, B. Vandekerckhove, G. Leclercq, 2017, Oncoimmunology.

CAR and TCR form individual signaling synapses and do not cross-activate, however, can co-operate in T cell activation

L. Veľas, G. Vereb, H. Abken, 2023, Frontiers in Immunology.

Building on Synthetic Immunology and T Cell Engineering: A Brief Journey Through the History of Chimeric Antigen Receptors

H. Abken, 2021, Human gene therapy.

A CD19-Anti-ErbB2 scFv Engager Protein Enables CD19-Specific CAR T Cells to Eradicate ErbB2+ Solid Cancer

C. Ambrose, H. Abken, P. Rennert, 2023, Cells.

Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies

R. Herwig, M. Peifer, M. Hallek, 2022, Blood.

CD7(-) T cells are late memory cells generated from CD7(+) T cells.

J. Becker, A. Schmidt, D. Schrama, 2008, Rejuvenation research.

Endogenous Il10 alleviates the systemic antiviral cellular immune response and T cell-mediated immunopathology in select organs of acutely LCMV-infected mice.

G. Rappl, A. Brunn, M. Deckert, 2015, The American journal of pathology.

Concepts in mature T-cell lymphomas – highlights from an international joint symposium on T-cell immunology and oncology*

R. Küppers, M. Hansmann, M. Herling, 2017, Leukemia & lymphoma.

IL12 integrated into the CAR exodomain converts CD8+ T cells to poly-functional NK-like cells with superior killing of antigen-loss tumors

H. Abken, A. Sachinidis, A. Hombach, 2021, Molecular therapy : the journal of the American Society of Gene Therapy.

Superior Therapeutic Index in Lymphoma Therapy: CD30+ CD34+ Hematopoietic Stem Cells Resist a Chimeric Antigen Receptor T-cell Attack.

H. Abken, B. Giebel, A. Görgens, 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

STRIP2 Is Indispensable for the Onset of Embryonic Stem Cell Differentiation

V. Wagh, J. Hescheler, H. Abken, 2017, Molecular therapy. Methods & clinical development.

FimH-based display of functional eukaryotic proteins on bacteria surfaces

M. Hallek, H. Abken, J. Kuehle, 2019, Scientific Reports.

TRUCKs with IL‐18 payload: Toward shaping the immune landscape for a more efficacious CAR T‐cell therapy of solid cancer

H. Abken, M. Chmielewski, 2018 .

PECAM1+/Sca1+/CD38+ Vascular Cells Transform into Myofibroblast-Like Cells in Skin Wound Repair

M. Paulsson, J. Etich, H. Abken, 2013, PloS one.

Second mitochondria-derived activator of caspase (SMAC) mimetic potentiates tumor susceptibility toward natural killer cell-mediated killing

H. Abken, M. Krönke, H. Kashkar, 2014, Leukemia & lymphoma.

Analysis of the functional WT1-specific T-cell repertoire in healthy donors reveals a discrepancy between CD4+ and CD8+ memory formation

E. Gostick, H. Abken, M. Assenmacher, 2015, Immunology.

IRF4 downregulation improves sensitivity and endurance of CAR T cell functional capacities

H. Abken, J. Hartley, W. Herr, 2023, Frontiers in Immunology.

The recombinant T cell receptor strategy: insights into structure and function of recombinant immunoreceptors on the way towards an optimal receptor design for cellular immunotherapy.

H. Abken, A. Hombach, C. Heuser, 2002, Current gene therapy.

Correction: Nemade, H.; et al. Cyclooxygenases Inhibitors Efficiently Induce Cardiomyogenesis in Human Pluripotent Stem Cells. Cells 2020, 9, 554

J. Hescheler, H. Abken, A. Sachinidis, 2020, Cells.

Adoptive transfer of chimeric antigen receptor-T regulatory cells as an effective therapy for allergic asthma

G. Hansen, H. Abken, C. Happle, 2014 .

Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 "super-stimulation".

H. Abken, A. Hombach, G. Rappl, 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

Antibody-based immunoreceptors: the impact of signalling domain, binding affinity and costimulation

H. Abken, A. Hombach, C. Heuser, 2004, Cancer Cell International.

CAR T cells targeting solid tumors: carcinoembryonic antigen (CEA) proves to be a safe target

H. Abken, A. Holzinger, 2017, Cancer Immunology, Immunotherapy.

Abstract A09: GPR64-specific CAR-transgenic T cells selectively kill Ewing sarcoma in vivo

S. Burdach, H. Abken, R. Feederle, 2018, Poster Presentations - Proffered Abstracts.

Analysis of the functional WT1-speciﬁc T-cell repertoire in healthy donors reveals a discrepancy between CD4 + and CD8 + memory formation

E. Gostick, H. Abken, M. Assenmacher, 2023 .

Costimulation Engages the Gear in Driving CARs.

H. Abken, 2016, Immunity.

Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease.

H. Heslop, C. Rooney, H. Abken, 2007, Blood.

Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas

B. Seliger, A. Moosmann, T. Blankenstein, 2008, Proceedings of the National Academy of Sciences.

Adoptive immunotherapy with redirected T cells produces CCR7- cells that are trapped in the periphery and benefit from combined CD28-OX40 costimulation.

H. Abken, A. Hombach, M. Chmielewski, 2013, Human Gene Therapy.

Adoptive therapy with CAR redirected T cells: the challenges in targeting solid tumors.

H. Abken, 2015, Immunotherapy.

Conditions of retinal glial and inflammatory cell activation after irradiation in a GFP-chimeric mouse model.

A. Joussen, M. Beyer, K. L. Meyer, 2010, Investigative ophthalmology & visual science.

FimH-based display of functional eukaryotic proteins on bacteria surfaces

M. Hallek, H. Abken, J. Kuehle, 2019, Scientific Reports.

Depletion of annexin A5, annexin A6, and collagen X causes no gross changes in matrix vesicle–mediated mineralization, but lack of collagen X affects hematopoiesis and the Th1/Th2 response

U. Schlötzer-Schrehardt, M. Paulsson, A. Niehoff, 2012, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

Chimeric antigen receptor T cells targeting Fc μ receptor selectively eliminate CLL cells while sparing healthy B cells.

C. Wendtner, H. Abken, L. Frenzel, 2016, Blood.

CAR's made it to the pancreas

Z. Eshhar, H. Abken, M. Chmielewski, 2012, Oncoimmunology.

Do CARs need a driver's license? Adoptive cell therapy with chimeric antigen receptor-redirected T cells has caused serious adverse events.

W. Uckert, K. Cichutek, H. Büning, 2010, Human gene therapy.

Immune response manipulation: recombinant immunoreceptors endow T-cells with predefined specificity.

H. Abken, A. Hombach, C. Heuser, 2003, Current pharmaceutical design.

CAR T cells as micropharmacies against solid cancers: Combining effector T-cell mediated cell death with vascular targeting in a one-step engineering process

A. Schambach, W. Berdel, W. Hartmann, 2023, Cancer Gene Therapy.

Combining cytokine-induced killer cells with vaccination in cancer immunotherapy: more than one plus one?

I. Schmidt-Wolf, H. Abken, S. Thanendrarajan, 2011, Leukemia research.